Validating the diagnostic efficacy of NADK2 in a clinical dataset
(A) Expression levels of NADK2 in the control group and discogenic sciatica (n = 100/group).
(B and C) LASSO regression analysis with 10-fold cross-validation on clinical data.
(D) Diagnostic ROC curve validating the diagnostic value of NADK2 expression for sciatica.
(E and F) Further validation of the diagnostic value of NADK2 using diagnostic curve analysis and diagnostic calibration curve. ∗∗∗p < 0.001.